Home/Indications/Allergic Conjunctivitis

Allergic Conjunctivitis

0 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Phase 3 Readouts Pro

1 active Phase 3 trial with confidence-graded completion dates.

Full calendar →

Q1 2027

REGN5713

Regeneron

Estimated · fresh NCT07309432

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 2 mechanisms across 5 industry trials with a known mechanism of action.

See full pipeline →

Corticosteroid

4 trials 2 sponsors

Lymphocyte Function-Associated Antigen-1 Antagonist

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

92 industry-sponsored trials across 35 sponsors

Showing 19 of 19 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Laboratorios Poen	Bepotastine Besilate 1.5% PF	—	COMPLETED	2022-08-18	NCT04776096
Andover Research Eye Institute	olopatadine hydrochloride ophthalmic solution 0.7%)	—	COMPLETED	2022-07-24	NCT05314621
Andover Research Eye Institute	olopatadine hydrochloride ophthalmic solution 0.7%	—	COMPLETED	2022-04-23	NCT05265910
ORA, Inc.	Lastacaft ®	—	COMPLETED	2015-02	NCT02308501
Alcon Research	Olopatadine HCl ophthalmic solution, 0.1%	—	COMPLETED	2014-01	NCT02251613
Alcon Research	Olopatadine hydrochloride ophthalmic solution, 0.2%	—	COMPLETED	2013-07	NCT01697969
ORA, Inc.	Prednisolone Sodium Phosphate Ophthalmic Solution 1%	—	COMPLETED	2012-12	NCT01730872
Minnesota Eye Consultants, P.A.	Refresh Tears 0.5% Lubricant Eye Drops	—	COMPLETED	2012-08	NCT01346371
ORA, Inc.	Prednisolone Sodium Phosphate Ophthalmic Solution 1%	—	COMPLETED	2012-02	NCT01534195
Alcon Research	Olopatadine Hydrochloride Ophthalmic Solution, 0.2%	—	COMPLETED	2011-12	NCT01272089
ORA, Inc.	Fluticasone Propionate Nasal Spray	—	COMPLETED	2011-10	NCT01439815
Alcon Research	AL-4943A	—	COMPLETED	2011-10	NCT01294969
Alcon Research	Olopatadine hydrochloride ophthalmic solution 0.1%	—	COMPLETED	2011-07	NCT01109485
Alcon Research	Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)	—	COMPLETED	2011-03	NCT01282138
Alcon Research	Dexamethasone 0.1% ophthalmic suspension	—	COMPLETED	2010-09	NCT01119287
Alcon Research	Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)	—	COMPLETED	2010-08	NCT01159769
Alcon Research	Olopatadine 0.1%	—	COMPLETED	2008-07	NCT00818805
ORA, Inc.	Prednisolone Acetate 1%	—	COMPLETED	2008-06	NCT00689078
Laboratoires Thea	NAABAK eyedrops	—	COMPLETED	—	NCT01203540

Showing 38 of 38 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Regeneron	REGN5713	—	RECRUITING	2027-02-28	NCT07309432
Regeneron	REGN1908	—	COMPLETED	2025-05-10	NCT06602726
Regeneron	REGN5713	—	COMPLETED	2025-04-23	NCT06602739
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln	—	COMPLETED	2023-11-02	NCT06212973
Bausch & Lomb Incorporated	Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)	—	COMPLETED	2023-09-18	NCT05815758
Bausch & Lomb Incorporated	Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution	—	COMPLETED	2023-08-09	NCT05591755
Bausch & Lomb Incorporated	Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%	—	COMPLETED	2023-07-22	NCT05579730
Aldeyra Therapeutics, Inc.	Reproxalap Ophthalmic Solution (0.25%)	—	COMPLETED	2023-04-22	NCT05234554
Faes Farma, S.A.	Bilastine	—	COMPLETED	2022-11-30	NCT04810390
Aldeyra Therapeutics, Inc.	Reproxalap Ophthalmic Solution (0.25%)	—	COMPLETED	2021-02-16	NCT04207736
Ocular Therapeutix, Inc.	Dexamethasone, 0.4mg	—	COMPLETED	2020-02-28	NCT04050865
Marinomed Biotech AG	Rhinocort	Corticosteroid [EPC]	COMPLETED	2019-04-05	NCT03755557
Aldeyra Therapeutics, Inc.	Reproxalap Ophthalmic Solution (0.25%)	—	COMPLETED	2018-11-05	NCT03494504
Faes Farma, S.A.	Bilastine Ophthalmic Solution 0.6%	—	COMPLETED	2018-08-09	NCT03479307
Bausch & Lomb Incorporated	EM-100	—	COMPLETED	2018-04-29	NCT03489941
Ocular Therapeutix, Inc.	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2016-04-27	NCT02988882
Eleven Biotherapeutics	EBI-005	—	COMPLETED	2015-11	NCT02492321
Alcon Research	Olopatadine Hydrochloride Ophthalmic Solution 0.2%	—	COMPLETED	2015-10	NCT02322216
Ocular Therapeutix, Inc.	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2015-08	NCT02445326
Aciex Therapeutics, Inc.	Drug: AC-170 0.24%	—	COMPLETED	2014-10	NCT02132169
Aciex Therapeutics, Inc.	AC-170 0.24%	—	COMPLETED	2013-10	NCT01881113
Alcon Research	AL-4943A ophthalmic solution	—	COMPLETED	2013-07	NCT01743027
Alcon Research	AL-4943A Ophthalmic Solution	—	COMPLETED	2013-01	NCT01698814
Aciex Therapeutics, Inc.	AC-170 0.24%	—	COMPLETED	2012-11	NCT01685242
Stallergenes Greer	Birch pollen allergen extract	—	COMPLETED	2012-07	NCT01731249
Aciex Therapeutics, Inc.	AC-170 0.24%	—	COMPLETED	2012-06	NCT01551056
Akorn, Inc.	AKF-1	—	COMPLETED	2012-04	NCT01561521
Alcon Research	AL-4943A ophthalmic solution	—	COMPLETED	2012-03	NCT01479374
Aciex Therapeutics, Inc.	AC-170 0.05%	—	COMPLETED	2011-06	NCT01332188
Bausch & Lomb Incorporated	Loteprednol etabonate 0.2%	—	COMPLETED	2011-04	NCT01435460
Bausch & Lomb Incorporated	KetoNaph	—	COMPLETED	2010-09	NCT01159015
Alcon Research	Olopatadine Hydrochloride Ophthalmic Solution, 0.2%	—	COMPLETED	2010-05	NCT01037179
Bausch & Lomb Incorporated	Ketotifen/naphazoline	—	COMPLETED	2010-04	NCT00770133
Alcon Research	Olopatadine Hydrochloride Ophthalmic Solution, 0.2%	—	COMPLETED	2009-11	NCT00987272
Vistakon Pharmaceuticals	—	—	COMPLETED	2009-07	NCT00889252
Vistakon Pharmaceuticals	alcaftadine	—	COMPLETED	2009-05	NCT00889330
Bausch & Lomb Incorporated	Ketotifen/naphazoline	—	COMPLETED	2008-12	NCT00769886
Laboratorios Sophia S.A de C.V.	PRO-118	—	WITHDRAWN	2015-04	NCT01657240

Showing 30 of 30 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Telios Pharma, Inc.	TL-925	—	RECRUITING	2026-02	NCT07220408
Telios Pharma, Inc.	TL-925	—	RECRUITING	2024-12-10	NCT06686472
Telios Pharma, Inc.	TL-925	—	COMPLETED	2024-05-21	NCT06293820
Marinomed Biotech AG	Eye Drops, Solution in Single-Dose Container	—	COMPLETED	2021-05-27	NCT04532710
Vanda Pharmaceuticals	VSJ-110	—	COMPLETED	2021-05-22	NCT04622345
Aldeyra Therapeutics, Inc.	Reproxalap Ophthalmic Solution (0.25%)	—	COMPLETED	2019-11-19	NCT03660878
ORA, Inc.	PRT-2761 0.5%	—	COMPLETED	2018-02-16	NCT03320434
Realm Therapeutics, Inc.	PR013 (0.045%)	—	COMPLETED	2018-01-21	NCT03368339
Faes Farma, S.A.	Bilastine 0.2%	—	COMPLETED	2017-10-11	NCT03231969
Noveome Biotherapeutics, formerly Stemnion	ST266	—	COMPLETED	2017-02	NCT02978183
Aldeyra Therapeutics, Inc.	NS2 Ophthalmic Drops (0.5%)	—	COMPLETED	2015-12	NCT02578914
Ocular Therapeutix, Inc.	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2014-08	NCT02062905
Alcon Research	AL-53817 Ophthalmic Solution, 0.1%	—	COMPLETED	2014-07	NCT02079649
Eleven Biotherapeutics	Active Comparator EBI-005 5 mg/mL	—	COMPLETED	2014-06	NCT02082899
AbbVie	AGN-229666	—	COMPLETED	2013-01	NCT01754766
C.T. Development America, Inc.	RX-10045	—	COMPLETED	2012-08	NCT01639846
Laboratoires Thea	T1210	—	COMPLETED	2012-02	NCT01344083
Sun Pharma Advanced Research Company Limited	SPARC1102 I	—	COMPLETED	2011-08	NCT01320553
Eye Therapies, LLC	Vehicle	—	COMPLETED	2011-03	NCT01275105
Bausch & Lomb Incorporated	bepotastine besilate ophthalmic solution	—	COMPLETED	2010-10	NCT01174823
Fovea Pharmaceuticals SA	CsA high dose	—	COMPLETED	2010-08	NCT01120132
Aciex Therapeutics, Inc.	AC-150 Combo	—	COMPLETED	2010-07	NCT01134328
Bausch & Lomb Incorporated	Loteprednol etabonate base (QD)	—	COMPLETED	2010-05	NCT01107405
Alcon Research	AL-38583 ophthalmic solution	—	COMPLETED	2010-04	NCT01001091
Takeda	Lifitegrast	Lymphocyte Function-Associated Antigen-1 Antagonist [EPC]	COMPLETED	2009-05-10	NCT00882687
Senju USA, Inc.	Ketotifen 4.0% Patch	—	COMPLETED	2009-03	NCT00836485
Fovea Pharmaceuticals SA	Prednisolone Acetate 0.12% (Pred Mild®)	—	COMPLETED	2009-03	NCT00833495
Mati Therapeutics Inc.	Olopatadine	—	TERMINATED	2011-01	NCT01287338
Laboratorios Sophia S.A de C.V.	PRO-118 Ophthalmic Solution 0.015%	—	WITHDRAWN	2012-02	NCT01541904
Alcon Research	AL38583 Ophthalmic Solution	—	WITHDRAWN	2009-05	NCT00881673

Showing 5 of 5 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shanghai Medinno Pharmaceutical Technology Co., Ltd.	MDI-1228_mesylate Ophthalmic Solution	—	COMPLETED	2024-04-30	NCT05969236
Allakos Inc.	AK002	—	COMPLETED	2019-08-08	NCT03379311
Xencor, Inc.	XmAb7195	—	COMPLETED	2015-09-21	NCT02148744
Alcon Research	Olopatadine hydrochloride ophthalmic solution, 0.7%	—	COMPLETED	2011-06	NCT01326858
Woodmont Pharmaceuticals, Inc.	Dose Level 1	—	TERMINATED	2017-04-29	NCT03038971

Novel Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (7 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.